Accessibility Menu
Singular Genomics Systems logo

Singular Genomics Systems(NASDAQ) OMIC

This security has been delisted. This page is retained for historical reference.

Singular Genomics Systems last closing stock price
MetricPriceDate
Last closeUSD 20.012025-02-20
Singular Genomics Systems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.35%USD 19.942025-02-13
1 month+1.57%USD 19.702025-01-21
3 month-6.58%USD 21.422024-11-22
Year to date+2.99%USD 19.432024-12-31
1 year+30.78%USD 15.302024-02-21
3 year-90.7%USD 215.102022-02-18
Since inception-97.41%USD 771.602021-05-27

OMIC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

OMIC Financials

Key Financial Metrics (TTM)

Gross Margin

-19.17%

Operating Margin

-3531.47%

Net Income Margin

-3257.30%

Return on Equity

-43.17%

Return on Capital

-40.43%

Return on Assets

-35.72%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$3.08M

Operating Income

-$93.00M

EBITDA

-$78.33M

Operating Cash Flow

-$80.43M

Capital Expenditure

-$425.00K

Free Cash Flow

-$80.86M

Cash & ST Invst.

$113.83M

Total Debt

$50.49M

Singular Genomics Systems Performance Analysis

Singular Genomics Systems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 765,000N/A
20232023-12-31USD 2,911,000280.5%
Singular Genomics Systems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31134.0%
Q12024-03-31-59.1%
Q22024-06-3066.7%
Q32024-09-30-44.9%
Singular Genomics Systems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -40.91N/A
20222022-12-31USD -38.32-6.3%
20232023-12-31USD -39.082.0%
Singular Genomics Systems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-3.4%
Q12024-03-31-7.1%
Q22024-06-3015.6%
Q32024-09-3021.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$406.00K

-12.1%

Gross Profit

-$301.00K

-363.1%

Gross Margin

-74.14%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

255

N/A

Net Income

-$16.80M

+24.9%

EBITDA

-$14.82M

+26.7%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$113.83M

-40.3%

Total Debt

$50.49M

-34.4%

Accounts Receivable

$1.01M

-69.6%

Inventory

$12.41M

-7.5%

Long Term Debt

$45.02M

-35.0%

Short Term Debt

$5.47M

-64.5%

Return on Assets

-35.72%

N/A

Return on Invested Capital

-41.59%

N/A

Free Cash Flow

-$19.80M

-17.0%

Operating Cash Flow

-$19.79M

-17.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GCTKGlucoTrack, Inc.
$0.30+4.36%
ALVRAlloVir, Inc.
$9.81+4.14%
BLUEbluebird bio, Inc.
$4.97+0.00%
KRONKronos Bio, Inc.
$0.88+1.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.